DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "HIV Diagnosis Market by Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification, Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) - Global Forecast to 2021" report to their offering.
The HIV diagnosis market is projected to reach USD 3.88 Billion by 2021 from USD 2.35 Billion in 2016, at a CAGR of 10.5% from 2016 to 2021.
Factors such as the growing worldwide prevalence of HIV/AIDS, increasing number of blood transfusions and blood donations, benefits offered by point-of-care instruments and kits, and increasing government initiatives are expected to drive the growth of the market worldwide.
This market is segmented based on product, test type, end user, and region. On the basis of product, the market is segmented into consumable (assays, kits, reagents, and other consumables), instruments, and software & services. In 2016, the consumables segment is expected to account for the largest share of the market due to the frequent and repetitive purchase of assays, kits, and reagents by laboratories, hospitals, and blood banks and also due to advancements in PoC testing.
On the basis of test type, the HIV diagnosis market is classified into antibody tests, viral load tests, CD4 count tests, tests for early infant diagnosis, and tests for viral identification. The antibody tests segment is further divided into HIV-1 screening tests, HIV-1 confirmatory tests, and HIV-2 and Group O diagnostic tests. The antibody tests segment is expected to account for the largest share of the market in 2016. This large share can be attributed to high prevalence of HIV/AIDS, increasing awareness about HIV/AIDS, increasing blood donations and advancements, and better offerings from PoC testing.
On the basis of end user, the HIV diagnosis market is divided into diagnostic laboratories, hospitals, blood banks, home care settings, and others (gene banks, cell banks, biotechnology and pharmaceutical companies, and academic research institutes). The diagnostic laboratories segment is expected to account for the largest share of market in 2016. This large share is mainly due to high investment and technological advancements of diagnostics laboratories and increasing awareness of HIV/AIDS
- Growing Worldwide Prevalence of Hiv/Aids
- Increasing Number of Blood Transfusions And Blood Donations
- Benefits Offered By Point-Of-Care Instruments & Kits
- Increasing Government Initiatives
- High Cost of Nat
- Lack of Mandates for Nat in Developing Countries
- Emerging Economies Offer Lucrative Growth Opportunities for Hiv Diagnostics
- Increase in Use of Home Access Kits And Instruments
- Abbott Laboratories
- Alere Inc.
- Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
- Becton, Dickinson & Company
- Bio-Rad Laboratories
- Hologic Inc.
- Merck Kgaa
- Roche Diagnostics (Division of Hoffman La Roche Ltd.)
- Siemens Healthineers (A Division of Siemens Ag)
- Thermo-Fisher Scientific Inc.
For more information about this report visit http://www.researchandmarkets.com/research/7749ws/hiv_diagnosis